Peptic ulcer disease (PUD) is one of the most common GI conditions nursing students encounter in both med-surg and critical care settings. Affecting approximately 4.5 million Americans annually, PUD involves mucosal defects in the stomach or proximal duodenum that penetrate through the protective epithelial layer into deeper tissue. Two primary mechanisms account for most cases: infection with Helicobacter pylori and chronic NSAID use. Left untreated, PUD progresses to serious — occasionally life-threatening — complications including hemorrhage and perforation.
This reference covers the full scope of PUD nursing: pathophysiology, gastric vs duodenal ulcer differences, assessment findings, diagnostic workup, priority nursing interventions, medical management including H. pylori eradication therapy, and high-yield NCLEX tips. For related GI content, see the GI bleed nursing reference and peritonitis nursing reference.
| Quick reference | Detail |
|---|---|
| Definition | Mucosal erosion in the stomach or duodenum penetrating through the muscularis mucosae |
| Most common cause | H. pylori infection (~70–85% of gastric ulcers; ~90–95% of duodenal ulcers) |
| Second most common cause | Chronic NSAID use (inhibits prostaglandin-mediated mucosal protection) |
| Gastric ulcer pain pattern | Epigastric pain worsened by eating; nausea and anorexia common |
| Duodenal ulcer pain pattern | Epigastric pain relieved by eating; returns 2–3 hours postprandial; nocturnal pain classic |
| First-line eradication therapy | PPI + clarithromycin + amoxicillin × 14 days (triple therapy) |
| Priority nursing concern | Monitor for hemorrhage: hematemesis, melena, dropping H&H, hemodynamic instability |
| Surgical emergency sign | Sudden severe epigastric pain + board-like rigid abdomen = perforation until proven otherwise |
Pathophysiology
The gastric mucosa is protected by a mucosal barrier composed of mucus, bicarbonate secretion, epithelial tight junctions, and prostaglandin-driven blood flow. PUD develops when this barrier is overwhelmed by acid and pepsin, or when barrier-maintaining mechanisms are disrupted.
H. pylori mechanism
Helicobacter pylori is a gram-negative, spiral-shaped bacterium that colonizes beneath the mucous layer. It produces urease, which converts urea to ammonia and CO₂. The ammonia neutralizes local pH, allowing the bacterium to survive in the acidic gastric environment and enabling direct contact with epithelial cells.
Beyond urease, virulent H. pylori strains carry the CagA pathogenicity island and VacA vacuolating cytotoxin. CagA is injected into gastric epithelial cells via a bacterial type IV secretion system, disrupting cell polarity and signaling. VacA induces cellular vacuolation, apoptosis, and mitochondrial dysfunction. The resulting chronic inflammatory response (predominantly Th1/Th17) further degrades the mucosal barrier. In the duodenum, H. pylori infection of antral mucosa increases gastrin secretion, raising acid output and creating an environment favorable to duodenal ulcer formation.
NSAID-related damage
NSAIDs inhibit cyclooxygenase-1 (COX-1), the isoform responsible for constitutive prostaglandin synthesis in the GI tract. Prostaglandins — particularly PGE₂ and PGI₂ — stimulate mucus and bicarbonate secretion, promote epithelial cell turnover, and maintain mucosal blood flow. When COX-1 is inhibited, these protective mechanisms are impaired. The mucosal barrier thins, epithelial repair slows, and local ischemia increases vulnerability to acid damage. NSAID-related ulcers frequently present without pain (especially in older adults), making occult hemorrhage a significant clinical concern.
Zollinger-Ellison syndrome
In a minority of cases, PUD is caused by a gastrinoma — a neuroendocrine tumor that secretes gastrin autonomously (Zollinger-Ellison syndrome). Excessive gastrin drives massive acid hypersecretion, producing multiple, recurrent, and often refractory ulcers. Standard H. pylori eradication does not resolve Zollinger-Ellison ulcers; high-dose PPI therapy and tumor resection are required.
Gastric vs duodenal ulcers
The location of an ulcer determines its pain pattern, associated symptoms, and risk profile. NCLEX frequently tests the differences between gastric and duodenal ulcers.
| Feature | Gastric ulcer | Duodenal ulcer |
|---|---|---|
| Location | Stomach wall (most commonly antrum or lesser curvature) | First part of duodenum (D1), within 2 cm of pylorus |
| Prevalence | Less common than duodenal (~20% of PUD) | More common (~80% of PUD) |
| H. pylori association | ~70–85% | ~90–95% |
| Pain timing | During or immediately after eating — food triggers acid contact with ulcer | 2–3 hours postprandial; classic nocturnal pain (acid secretion peaks at night) |
| Effect of food on pain | Worsens pain | Temporarily relieves pain (food buffers gastric acid) |
| Nausea/anorexia | Common — patients often avoid eating due to pain | Less prominent |
| Weight loss | Common (food avoidance) | Uncommon; patients may overeat to buffer pain |
| Malignancy risk | Gastric ulcers require biopsy to rule out malignancy | Duodenal ulcers are almost never malignant |
| Acid secretion | Normal or reduced (mucosal defect, not hypersecretion) | Often increased (hypersecretion + impaired duodenal buffering) |
Clinical presentation and assessment
Symptoms
- Epigastric pain — burning, gnawing, or aching; the hallmark symptom of both ulcer types
- Hematemesis — vomiting bright red blood (active bleeding) or coffee-ground material (digested blood from slower bleeding)
- Melena — black, tarry, foul-smelling stool indicating upper GI bleeding (≥50–100 mL of blood in the GI tract)
- Hematochezia — bright red blood per rectum; occurs only with massive, rapid upper GI hemorrhage (>1,000 mL)
- Nausea and bloating
- Early satiety — particularly in gastric ulcers or when gastric outlet obstruction develops
- Weight loss — common with gastric ulcers due to food avoidance
Signs of complications
| Finding | Clinical significance |
|---|---|
| Sudden severe epigastric pain with board-like rigid abdomen | Perforation — surgical emergency |
| Rebound tenderness, involuntary guarding | Peritoneal irritation from perforation |
| Cullen’s sign (periumbilical bruising) | Retroperitoneal hemorrhage — rare with PUD; more classic for pancreatitis |
| Grey-Turner’s sign (flank bruising) | Retroperitoneal hemorrhage |
| Orthostatic hypotension, tachycardia | Significant hemorrhage with volume depletion |
| Projectile vomiting, distension, succussion splash | Gastric outlet obstruction |
| Positive fecal occult blood test | Occult GI bleeding |
Vital sign patterns in hemorrhagic PUD
- Early hemorrhage: tachycardia (HR >100), normal or slightly low BP
- Progressive hemorrhage: hypotension, narrowing pulse pressure, cool/clammy skin, decreased urine output
- Compensated vs decompensated: young patients may maintain BP until significant volume is lost — tachycardia often precedes hypotension
Diagnostic workup
H. pylori testing
| Test | Method | Notes |
|---|---|---|
| Urea breath test (UBT) | Patient ingests ¹³C- or ¹⁴C-labeled urea; H. pylori urease cleaves it → labeled CO₂ detected in breath | Non-invasive; preferred for diagnosis and confirmation of eradication; must hold PPIs 2 weeks, antibiotics 4 weeks prior |
| Stool antigen test | Detects H. pylori antigens in stool via immunoassay | Non-invasive; useful for initial diagnosis and post-treatment confirmation; hold PPIs 2 weeks prior |
| Rapid urease test (CLO test) | Endoscopic biopsy placed in urea-containing medium; color change indicates urease activity | Performed during endoscopy; fast result; hold PPIs and antibiotics before testing |
| Histology (biopsy) | Endoscopic biopsy with microscopic examination | Gold standard; also rules out malignancy in gastric ulcers; required for all gastric ulcers regardless of H. pylori status |
| Serology (IgG antibody) | Detects anti-H. pylori IgG in serum | Cannot distinguish active from past infection; not appropriate for post-treatment confirmation; limited diagnostic utility |
Other diagnostic tests
- Upper endoscopy (EGD) — definitive; visualizes ulcer location, depth, and stigmata of recent hemorrhage (active bleeding, visible vessel, clot); allows biopsy for malignancy and H. pylori
- Complete blood count — hemoglobin and hematocrit assess degree of blood loss; MCV may be low (microcytic) with chronic occult bleeding (iron-deficiency pattern)
- Fecal occult blood test (FOBT/guaiac) — screens for blood not visible on inspection; positive result warrants endoscopy
- Serum gastrin level — elevated (>1,000 pg/mL) in Zollinger-Ellison syndrome
- Abdominal X-ray / chest X-ray — free air under the diaphragm on upright CXR = perforation (pneumoperitoneum); absent bowel sounds + rigidity without imaging = don’t wait for X-ray in a crashing patient
- BMP/CMP — baseline electrolytes, BUN; elevated BUN-to-creatinine ratio (>20:1) suggests upper GI bleed (blood digested and absorbed as protein)
Nursing interventions
| Intervention | Rationale |
|---|---|
| Establish large-bore IV access (≥18g, two sites if hemorrhage suspected) | Ensures capacity for rapid fluid resuscitation and blood product administration if active bleeding develops |
| Monitor vital signs every 1–4 hours; continuously in active hemorrhage | Tachycardia and hypotension are early indicators of hemodynamic compromise from GI blood loss |
| Monitor hemoglobin, hematocrit, BUN, and creatinine per orders | H&H trends identify ongoing or occult blood loss; rising BUN with stable creatinine (>20:1 ratio) confirms upper GI bleeding |
| Test all emesis and stool for blood (guaiac/fecal occult) | Quantifies occult blood loss not visible on inspection; guides transfusion and intervention decisions |
| Record strict intake and output, including emesis volume | Tracks fluid balance; urine output <0.5 mL/kg/hr indicates inadequate perfusion from volume depletion |
| Administer prescribed PPIs (IV or oral) and monitor response | Proton pump inhibitors raise gastric pH, reducing acid-mediated ulcer irritation and promoting mucosal healing; IV route used for active hemorrhage |
| Administer H. pylori eradication regimen as prescribed; educate on full course completion | Eradication reduces recurrence rate from ~80% (untreated) to <5%; incomplete courses promote antibiotic resistance |
| Position patient with HOB elevated 30–45° during and after meals | Reduces gastroesophageal reflux and nocturnal acid pooling; decreases aspiration risk if vomiting occurs |
| Instruct patient to avoid NSAIDs, aspirin, alcohol, tobacco, and caffeine | NSAIDs and aspirin inhibit prostaglandin-mediated mucosal protection; alcohol and tobacco impair mucosal healing and increase acid secretion |
| Provide small, frequent meals; counsel on bland diet avoidance myth | Small meals buffer acid without distending the stomach; research does not support strict bland diets — patients should avoid foods that worsen their specific symptoms |
| Assess pain level before and after meals using a validated scale; document pattern | Pain timing (worsened vs relieved by eating) distinguishes gastric from duodenal ulcer and tracks treatment response |
| Prepare patient for endoscopy (NPO, consent, IV access, sedation monitoring) | EGD is the diagnostic and therapeutic standard; endoscopic hemostasis (epinephrine injection, clipping, thermal therapy) controls active bleeding |
| Assess for signs of perforation every shift: sudden pain escalation, rigidity, absent bowel sounds | Perforation is a surgical emergency; early recognition reduces mortality; do not administer pain medication that might mask assessment findings without MD order |
| Provide emotional support and address anxiety around cancer fear | Patients with gastric ulcers requiring biopsy are often anxious about malignancy; honest, clear communication improves adherence and reduces distress |
Medical management
Acid suppression
Proton pump inhibitors (PPIs) are the cornerstone of PUD treatment. They irreversibly inhibit the H⁺/K⁺-ATPase pump on parietal cells, producing sustained acid suppression (>90% reduction in acid output). Standard dosing: omeprazole 20 mg, lansoprazole 30 mg, or pantoprazole 40 mg once or twice daily. IV pantoprazole is used for active upper GI hemorrhage.
H2 receptor antagonists (H2RAs) — famotidine, ranitidine (withdrawn), cimetidine — block histamine-2 receptors on parietal cells, reducing acid secretion by approximately 70%. Less potent than PPIs and subject to tolerance with continued use; largely replaced by PPIs in active PUD treatment but still used for maintenance and GERD.
Sucralfate forms a viscous, adherent barrier over the ulcer base, protecting it from acid and pepsin without altering gastric pH. Useful as adjunctive therapy, particularly for NSAID-related ulcers. Must be given on an empty stomach 30–60 minutes before meals — the barrier requires low pH to polymerize.
Bismuth compounds (bismuth subsalicylate) have direct bactericidal activity against H. pylori, coat the ulcer bed, and inhibit pepsin activity. Used as part of quadruple therapy for resistant or retreatment cases.
Misoprostol is a prostaglandin E1 analog that stimulates mucus and bicarbonate secretion and directly protects the gastric mucosa. Used prophylactically in patients who must continue NSAID therapy (e.g., for rheumatoid arthritis). Key nursing note: misoprostol is contraindicated in pregnancy (induces uterine contractions).
H. pylori eradication therapy
Eradicating H. pylori is the most important intervention in H. pylori-positive PUD. Recurrence rates drop from approximately 80% per year without treatment to under 5% after successful eradication.
Standard triple therapy (14 days):
- PPI (standard dose twice daily)
- Clarithromycin 500 mg twice daily
- Amoxicillin 1,000 mg twice daily
If penicillin allergy: substitute metronidazole 500 mg twice daily for amoxicillin.
Clarithromycin resistance rates exceeding 15–20% in a region make triple therapy less effective. The 14-day course outperforms 7-day and 10-day courses in eradication rates.
Bismuth quadruple therapy (10–14 days) — used for:
- First-line in areas of high clarithromycin resistance
- Retreatment after failed triple therapy
- Penicillin allergy with prior metronidazole exposure
Components: PPI (twice daily) + bismuth subsalicylate (four times daily) + tetracycline 500 mg (four times daily) + metronidazole 500 mg (three to four times daily).
Confirmation of eradication: Urea breath test or stool antigen test at least 4 weeks after completing antibiotics and 2 weeks after stopping PPIs. Serology cannot confirm eradication — IgG antibodies remain elevated for months after successful treatment.
Complications
Hemorrhage
The most common PUD complication, occurring in 15–20% of patients. Presentations range from occult blood in stool to massive hematemesis with hemodynamic collapse. Risk is highest with posterior duodenal ulcers (proximity to the gastroduodenal artery) and giant ulcers >2 cm. Nursing priorities: two large-bore IVs, fluid resuscitation, serial H&H, stool guaiac, preparation for emergent endoscopy. Transfuse packed red blood cells for Hgb <7 g/dL in stable patients (or <8 g/dL in those with cardiovascular disease or active bleeding).
For more detail on hemorrhage assessment and interventions, see the GI bleed nursing reference.
Perforation
Accounts for approximately 2–10% of PUD cases but carries a mortality of 1.3–20% depending on time to surgery. Anterior duodenal ulcers perforate into the peritoneal cavity most commonly. Classic triad: sudden severe epigastric pain (“like a knife”), rigid board-like abdomen, free air on upright CXR or CT (pneumoperitoneum). Bowel sounds are absent. This is a surgical emergency — emergent laparotomy or laparoscopic repair is required. Nursing: NPO, large-bore IV access, IV antibiotics as ordered, NG tube to decompress, Foley catheter for urine output monitoring, prepare for OR.
See the peritonitis nursing reference for the full nursing management of peritoneal contamination.
Gastric outlet obstruction
Chronic inflammation and edema near the pylorus or duodenal bulb can obstruct gastric emptying. Acute obstruction: mucosal edema (potentially reversible with PPI therapy and NG decompression). Chronic obstruction: fibrosis and scarring requiring endoscopic balloon dilation or surgical pyloroplasty. Clinical findings: projectile non-bilious vomiting, epigastric distension, succussion splash (fluid sloshing audible on shaking the patient), weight loss, dehydration, and hypochloremic hypokalemic metabolic alkalosis (from loss of HCl in vomit).
Malignant transformation
Gastric ulcers (unlike duodenal ulcers) can harbor or progress to gastric adenocarcinoma. All gastric ulcers require endoscopic biopsy at diagnosis and repeat endoscopy after 8–12 weeks of treatment to confirm healing. Failure to heal raises strong suspicion for malignancy. Chronic H. pylori infection is a recognized carcinogen (IARC Group 1) — eradication reduces but does not eliminate long-term gastric cancer risk.
Penetration
Ulcers may erode through the stomach or duodenal wall into adjacent structures without entering the peritoneum. Posterior gastric ulcers can penetrate into the pancreas, producing pain that radiates to the back and may be confused with pancreatitis. Elevated amylase/lipase may occur. Penetration is managed medically if contained; surgical intervention required for uncontrolled penetration.
NCLEX tips
-
Duodenal ulcer pain is relieved by food; gastric ulcer pain is worsened by food. This is the single most tested distinction for PUD on NCLEX. Memorize both directions.
-
Coffee-ground emesis = digested blood = slower or stopped upper GI bleed. Bright red hematemesis = active, rapid arterial bleeding. Both require urgent response but bright red blood indicates faster hemorrhage.
-
Melena vs hematochezia: Melena (black, tarry stool) = upper GI source. Hematochezia (bright red rectal blood) = lower GI source, OR massive rapid upper GI bleed. Either finding after a PUD diagnosis warrants immediate provider notification.
-
BUN-to-creatinine ratio >20:1 with no renal disease = upper GI bleed. Blood is digested as protein in the GI tract, raising BUN without a proportional rise in creatinine. NCLEX loves this lab pattern.
-
Sucralfate must be given before meals on an empty stomach. It requires an acidic environment to form its protective coating. Administering it with food or antacids (which raise pH) impairs its mechanism of action.
-
Misoprostol is contraindicated in pregnancy. It is a prostaglandin analog that stimulates uterine contractions and is used to induce labor/abortion. If a female patient of childbearing age is being started on misoprostol for NSAID gastroprotection, confirm pregnancy status first.
-
All gastric ulcers require repeat endoscopy after treatment to confirm healing. Duodenal ulcers do not require routine repeat endoscopy. This asymmetry exists because gastric ulcers can be malignant; duodenal ulcers are almost never malignant.
-
Perforation = surgical emergency. Sudden pain + rigid abdomen + free air on CXR = call the surgeon now. The nursing action is not to reposition or medicate — it is to notify the provider immediately and prepare for the OR.
-
Antibiotic resistance requires quadruple therapy, not triple therapy retreatment. If a patient fails a course of clarithromycin-based triple therapy, the next regimen is bismuth quadruple therapy — repeating the same triple regimen is inappropriate and risks further resistance.
-
Confirm H. pylori eradication with urea breath test or stool antigen test — not serology. IgG antibodies persist after successful eradication; serology will show false-positive results. NCLEX may ask which test is appropriate for post-treatment confirmation.
Related resources
- GI bleed nursing reference — hemorrhage assessment, Glasgow-Blatchford scoring, blood transfusion nursing
- Peritonitis nursing reference — peritoneal contamination from perforation, surgical emergency nursing
- Pancreatitis nursing reference — posterior ulcer penetration into pancreas; shared symptom patterns